• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

S2303：紫杉醇+雷莫西尤单抗±纳武利尤单抗用于胃和食管腺癌的II/III期试验（PARAMUNE）。

S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).

作者信息

Saeed Anwaar, Colby Sarah, Oberstein Paul Eliezer, Duda Dan G, Park Robin, Agarwal Rajiv, Figueroa-Moseley Colmar, Vaidya Riha, Unger Joseph M, Guthrie Katherine A, Rocha Flavio G, Senthil Maheswari, Safyan Rachael A, Wainberg Zev A, Iqbal Syma, Chiorean E Gabriela, Philip Philip A

机构信息

Department of Medicine, Division of Hematology & Oncology, UPMC Hillman Cancer Center, Pittsburgh, PL, USA.

SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA, USA.

出版信息

Future Oncol. 2025 May;21(11):1325-1331. doi: 10.1080/14796694.2025.2485020. Epub 2025 Mar 28.

DOI:10.1080/14796694.2025.2485020
PMID:40155326
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12051544/
Abstract

NCT06203600.

摘要

临床研究编号06203600

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465d/12051544/0b25d766b6da/IFON_A_2485020_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465d/12051544/bb087a2e4726/IFON_A_2485020_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465d/12051544/0b25d766b6da/IFON_A_2485020_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465d/12051544/bb087a2e4726/IFON_A_2485020_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465d/12051544/0b25d766b6da/IFON_A_2485020_F0002_OC.jpg

相似文献

1
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).S2303：紫杉醇+雷莫西尤单抗±纳武利尤单抗用于胃和食管腺癌的II/III期试验（PARAMUNE）。
Future Oncol. 2025 May;21(11):1325-1331. doi: 10.1080/14796694.2025.2485020. Epub 2025 Mar 28.
2
Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE).纳武单抗联合白蛋白结合型紫杉醇和雷莫西尤单抗用于一线治疗（包括氟嘧啶、铂类和抗PD-1/PD-L1抗体）进展后的不可切除晚期或复发性胃癌的II期试验（PADDLE）。
BMC Cancer. 2025 Feb 4;25(1):201. doi: 10.1186/s12885-025-13591-5.
3
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.雷莫芦单抗联合紫杉醇对比安慰剂联合紫杉醇治疗既往治疗的晚期胃或胃食管结合部腺癌患者（RAINBOW）：一项双盲、随机、III 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
4
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.雷莫西尤单抗联合紫杉醇作为晚期HER2阴性胃癌或胃食管交界癌患者一线奥沙利铂化疗后的转换维持治疗与继续治疗的比较（ARMANI）：一项随机、开放标签、多中心3期试验
Lancet Oncol. 2024 Dec;25(12):1539-1550. doi: 10.1016/S1470-2045(24)00580-1. Epub 2024 Nov 15.
5
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.雷莫西尤单抗联合或不联合紫杉醇每周给药作为晚期胃或胃食管交界腺癌二线治疗的疗效和安全性（RAINBOW-亚洲）：一项随机、多中心、双盲、3期试验
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. doi: 10.1016/S2468-1253(21)00313-7. Epub 2021 Oct 7.
6
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.二线 FOLFIRI 联合雷莫芦单抗治疗晚期胃食管腺癌的初步报告：多机构回顾性分析。
Oncologist. 2019 Apr;24(4):475-482. doi: 10.1634/theoncologist.2018-0602. Epub 2018 Nov 23.
7
Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.雷莫芦单抗治疗胃或胃食管结合部腺癌的疗效和安全性：系统评价和荟萃分析。
Eur J Clin Pharmacol. 2024 Nov;80(11):1697-1714. doi: 10.1007/s00228-024-03734-1. Epub 2024 Aug 5.
8
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.雷莫芦单抗用于治疗胃癌或胃食管连接部癌。
Expert Opin Biol Ther. 2019 Nov;19(11):1135-1141. doi: 10.1080/14712598.2019.1656715. Epub 2019 Aug 27.
9
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.雷莫西尤单抗联合FOLFOX作为晚期食管癌、胃食管交界癌或胃腺癌的一线治疗：一项随机、双盲、多中心II期试验。
Ann Oncol. 2016 Dec;27(12):2196-2203. doi: 10.1093/annonc/mdw423. Epub 2016 Oct 20.
10
Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.RAINBOW研究中东亚人群的亚组分析：雷莫西尤单抗联合紫杉醇治疗晚期胃癌的3期试验
J Gastroenterol Hepatol. 2016 Mar;31(3):581-9. doi: 10.1111/jgh.13153.

本文引用的文献

1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?食管癌新辅助免疫治疗：一个有前景的早期信号？
J Clin Oncol. 2024 Feb 1;42(4):373-377. doi: 10.1200/JCO.23.01982. Epub 2023 Nov 14.
3
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade.EDIL3 作为免疫检查点阻断后免疫排斥的血管生成靶点。
Cancer Immunol Res. 2023 Nov 1;11(11):1493-1507. doi: 10.1158/2326-6066.CIR-23-0171.
4
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.雷莫芦单抗联合帕博利珠单抗对比免疫治疗-肺癌-MAP S1800A 后治疗的晚期非小细胞肺癌的标准治疗的 II 期随机研究
J Clin Oncol. 2022 Jul 20;40(21):2295-2306. doi: 10.1200/JCO.22.00912. Epub 2022 Jun 3.
5
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌。
N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19.
6
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.帕博利珠单抗联合化疗与单纯化疗一线治疗晚期食管癌（KEYNOTE-590）：一项随机、安慰剂对照、III 期研究。
Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4.
7
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.一线纳武利尤单抗联合化疗与单纯化疗治疗晚期胃癌、胃食管交界癌和食管腺癌（CheckMate 649）：一项随机、开放标签的3期试验。
Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5.
8
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
9
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
10
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.免疫检查点抑制剂与 VEGF 靶向药物联合用于晚期胃和胃食管腺癌：早期临床试验的原理和结果综述。
J Hematol Oncol. 2021 Jan 12;14(1):13. doi: 10.1186/s13045-021-01034-0.